Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2916 Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus?

Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wetz C, Genseke P, Schatka I, Jann H, Rogasch J,

Keywords: Neuroendocrine Neoplasia, Asphericity, Everolimus, Prediction,

#2188 Predictive Markers of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)

Introduction: NET are relatively rare and up to still far from fully studied pathology. The frequency of NET GEP does not exceed 2% of all tumors of this localization.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Issaeva S, Khalimova Z, Safarova M, Gumarova A, Yuldashev A,

Keywords: gastroenteropancreatic neuroendocrine tumors, morphology, clinical,

#2143 Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams

Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Xu J

Authors: Jia R, Li Y, Jin Y, Chen Y, Zhang Y,

Keywords: NEC, checkpoint blockade, anti-PD-1 antibody, NENs,

#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors

Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Daskalakis K

Authors: Daskalakis K, Norlén O, Karakatsanis A, Hellman P, Larsson R,

Keywords: Ex vivo activity, Cytotoxic drugs, Targeted agents, small intestinal neuroendocrine tumors,

#1524 Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs)

Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lock A

Authors: Lock A, Wirtz R, Kaemmerer D, Haugvik S, Kure E,

Keywords: PREDICT-Study, everolimus, pNEN, gene signature, predictive marker,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.